Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705826 | 0.84 | KDM4E (0.53) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL6187789 | 0.82 | KDM4E (0.57) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL8225877 | 0.81 | KDM4E (0.50) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL27668658 | 0.80 | KDM4E (0.53) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL5578127 | 0.78 | KDM4E (0.47) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL21254106 | 0.77 | KDM4E (0.48) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL8509785 | 0.76 | KDM4E (0.53) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL11868873 | 0.76 | MAPT (0.47) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL11529414 | 0.76 | SMN1; SMN2 (0.48) | KDM4ENAPRTHCAR2ADORA3TSHR | |
| SCHEMBL78340 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023125825-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| US-4975112-A | STEREOISOMERS | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1990-12-04 | — | — | US | disclosed |
| EP-0119718-B1 | SMOKING COMPOSITIONS CONTAINING A NOVEL MONOACYLPYRAZINE FLAVORANT | Philip Morris Products Inc. (US) | 1989-05-10 | — | — | EP | disclosed |
| EP-0296722-A1 | Pyrazine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-12-28 | — | — | EP | disclosed |
| EP-0076085-A1 | Production of monoacylpyrazines | PHILIP MORRIS INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | KDM4E 893/4885NAPRT 2024/4885HCAR2 2690/4885 |
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TARDBP, GRN, NLN | KDM4E 3351/4885NAPRT 3684/4885HCAR2 3322/4885 |
| US-20070282100-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | KDM4E 3575/4885NAPRT 618/4885HCAR2 1026/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | KDM4E 2169/4885NAPRT 1109/4885HCAR2 1037/4885 |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | RIPK1, RIPK3, RIPK4 | KDM4E 3571/4885NAPRT 2775/4885HCAR2 1687/4885 |
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | KDM4E 3253/4885NAPRT 3686/4885HCAR2 4328/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | KDM4E 4410/4885NAPRT 3615/4885HCAR2 2984/4885 |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | CCR2, CCR1, CCR5 | KDM4E 3601/4885NAPRT 569/4885HCAR2 84/4885 |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | KDM4E 1851/4885NAPRT 3200/4885HCAR2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.